Tickers

1. Composite Trajectory Verdict

Given GRNT's upstream energy model — where production growth, commodity price realization, capital intensity, and covenant compliance are equally critical — the income statement, cash flow statement, and balance sheet carry roughly equal weight in assessing financial trajectory.

Composite Trajectory: Mixed

The annual income statement shows revenue growth (+18% FY2025 vs FY2024) and a net income rebound (+30% YoY), but operating income has declined for two consecutive years ($90.6M → $59.3M → $46.4M) and impairments have risen each year ($26.5M → $36.4M → $44.7M). Quarterly earnings are divergent: Q2 2026 net income rose 20% YoY, yet the first half of 2026 produced a $17.0M net loss versus a $34.9M profit in H1 2025, driven by a $59.0M derivative loss and higher interest expense. Cash flow from operations grew annually (+7.5% FY2025 vs FY2024) but fell 26% in H1 2026 vs H1 2025; free cash flow (operating less investing) deteriorated annually (-$53.8M → -$35.0M → -$113.4M) but improved in H1 2026 (-$16.8M vs -$46.4M). The balance sheet shows leverage rising sharply (total debt $205M → $400M → $475M) and equity declining ($635M → $606M → $562M), while liquidity fell from $339.5M to $293.8M in the first half of 2026. These offsetting moves — revenue and production up, but profitability, cash generation, and leverage metrics under pressure — yield a mixed composite picture.

2. Red Flags

• Derivative volatility swinging GAAP earnings: FY2025 recorded a $27.1M derivative gain, while H1 2026 recorded a $59.0M derivative loss (10-K 2025-12-31, MD&A Gain/(Loss) on Derivatives; 10-Q 2026-06-30, MD&A Gain/(Loss) on Derivatives).
• Interest expense escalation: Interest expense rose from $5.3M (FY2023) to $18.5M (FY2024) to $25.5M (FY2025) and $21.4M in H1 2026 alone (vs $10.9M in H1 2025) (10-K 2025-12-31, MD&A Interest Expense; 10-Q 2026-06-30, MD&A Interest Expense).
• Impairments accelerating: Annual impairments increased each year ($26.5M → $36.4M → $44.7M), and H1 2026 added $20.3M of unproved property impairments versus $0 in H1 2025 (10-K 2025-12-31, MD&A Impairment of Long-Lived Assets; 10-Q 2026-06-30, MD&A Impairment of Unproved Properties).
• Lease operating cost per Boe surging: FY2025 LOE/Boe rose to $7.27 from $6.29; H1 2026 LOE/Boe jumped to $9.91 from $6.60 in H1 2025 (10-K 2025-12-31, MD&A Results of Operations table; 10-Q 2026-06-30, MD&A Results of Operations table).
• Free cash flow deeply negative and worsening annually: FY2023 -$53.8M, FY2024 -$35.0M, FY2025 -$113.4M (operating cash flow minus investing cash flow) (10-K 2025-12-31, Consolidated Statements of Cash Flows).
• Leverage doubling in two years: Total debt increased from $205M (Dec 2024) to $400M (Dec 2025) to $475M (Jun 2026) while equity fell from $635M to $606M to $562M (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Note 8 Debt; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets).
• Liquidity declining in 2026: Liquidity dropped from $339.5M (Dec 2025) to $293.8M (Jun 2026) as credit facility borrowings rose $75M and cash rose only $29M (10-K 2025-12-31, MD&A Liquidity and Capital Resources; 10-Q 2026-06-30, MD&A Liquidity and Capital Resources).
• Current ratio near covenant floor: Current ratio fell from 1.25x (Dec 2025) to 1.02x (Jun 2026), close to the 1.00x minimum (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets).
• Dividends paid despite H1 2026 net loss: $29.0M of dividends paid in H1 2026 while reporting a $17.0M net loss (10-Q 2026-06-30, Condensed Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Consolidated Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Annual revenue grew 18% to $450.3M in FY2025 from $380.0M in FY2024, driven by a 28% increase in total production (11,674 MBoe vs 9,140 MBoe) that offset a 7% decline in realized price per Boe excluding derivatives ($38.57 vs $41.58) (10-K 2025-12-31, MD&A Results of Operations table). Net income rose 30% to $24.4M from $18.8M, but operating income fell for the second straight year to $46.4M from $59.3M, as impairments ($44.7M vs $36.4M) and interest expense ($25.5M vs $18.5M) increased (10-K 2025-12-31, Consolidated Statements of Operations; 10-K 2025-12-31, MD&A Interest Expense). Quarterly results diverge: Q2 2026 net income increased 20% YoY to $30.0M on 37% higher revenue ($149.3M vs $109.2M), yet H1 2026 swung to a $17.0M net loss from a $34.9M profit due to a $59.0M derivative loss, $21.4M interest expense, $20.3M impairments, and LOE/Boe of $9.91 vs $6.60 (10-Q 2026-06-30, Condensed Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A Results of Operations table). The mixed signal reflects production and revenue growth offset by rising costs, non-cash derivative losses, and leverage-related interest.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow modestly recovered to $296.4M in FY2025 from $275.7M in FY2024, but remained below the $302.9M generated in FY2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Investing outflows expanded to $409.8M from $310.8M, pushing free cash flow (operating less investing) to -$113.4M, a significant deterioration from -$35.0M in FY2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). In H1 2026, operating cash flow fell 26% to $113.9M from $154.1M in H1 2025, primarily due to a $34.6M realized derivative loss and $23.3M higher lease operating expenses, partially offset by $45.4M higher oil and gas sales (10-Q 2026-06-30, MD&A Cash Flows from Operating Activities). However, investing outflows declined to $130.7M from $200.5M, improving H1 free cash flow to -$16.8M from -$46.4M (10-Q 2026-06-30, Condensed Consolidated Statements of Cash Flows). Financing inflows surged in FY2025 ($118.8M vs $33.7M) on the $336M senior notes issuance, but H1 2026 financing inflows were only modestly higher ($46.0M vs $40.7M) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Consolidated Statements of Cash Flows). The trajectory is mixed: annual operating cash flow稳健 but free cash flow deeply negative and worsening; quarterly operating cash flow declined sharply while free cash flow improved on lower capex.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew 13% to $1.168B at Dec 2025 from $1.036B at Dec 2024, and a further 6% to $1.238B at Jun 2026 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets). However, total debt nearly doubled from $205M to $400M in 2025 (senior notes issuance) and rose another 19% to $475M by Jun 2026 (credit facility drawings) (10-K 2025-12-31, MD&A Liquidity and Capital Resources; 10-Q 2026-06-30, Note 8 Debt). Stockholders' equity declined from $635M (Dec 2024) to $606M (Dec 2025) to $562M (Jun 2026), with retained earnings turning to a $63.3M accumulated deficit from a $16.0M surplus at Dec 2024 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets). Liquidity improved annually from ~$129M (Dec 2024, estimated) to $339.5M (Dec 2025) but fell to $293.8M by Jun 2026 (10-K 2025-12-31, MD&A Liquidity and Capital Resources; 10-Q 2026-06-30, MD&A Liquidity and Capital Resources). The current ratio deteriorated from 1.25x to 1.02x, approaching the 1.00x covenant minimum (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets). Asset coverage and leverage covenants were met at Jun 2026, but the trend shows rising leverage, declining equity, and tightening liquidity.

6. Data Gaps

• Standalone Q1 2026 income statement (revenue, expenses, net income) — only net loss figure appears in the statement of changes in equity; a 10-Q for 2026-03-31 would fill this gap.
• Full-year 2023 production volumes (MBoe, Boe/d) and basin-level detail — the 10-K refers to the 2024 10-K for 2023 vs 2024 comparison; the 2024 10-K is not provided.
• EBITDAX or covenant-defined leverage ratio calculations — not disclosed in the provided filings; would require the Credit Agreement definitions and compliance certificates.
• Detailed breakdown of 2023 lease operating expenses, production taxes, and G&A per Boe — only 2024 and 2025 are shown in the 10-K MD&A table.
• Quarterly (Q1, Q3, Q4) 2025 cash flow statements — only annual and H1 2026 / H1 2025 are available; the 10-Qs for 2025-09-30 and 2025-06-30 are listed but not included in the provided documents.
• Proved reserve quantities and PV-10 values for 2024 and 2023 — only 2025 reserve data is referenced (NSAI evaluation); prior years' reserve reports are not in the provided filings.
• Schedule of debt maturities beyond the senior notes' quarterly amortization starting Sep 2026 — the 10-K notes only the $17.5M current portion; a full maturity schedule would require Note 8 of the 2025 10-K (not fully excerpted).